Glucose enters erythrocytes via a GLUT-1uniporter. As the levels of glucose in thebloodstream decrease between meals,what happens to the glucose in the cells?O Glucose remains in the cell because theGLUT-1 uniporters are gated and the gatesclose at low glucose concentrationsGlucose leaves the cell through the GLUT-1uniporter, traveling down the newconcentration gradient.Glucose remains in the cell becauseuniporters can only transport in onedirection.Glucose remains in the cell because it hasbeen phosphorylated to Glucose-6-phosphate and no longer has affinity for theGLUT-1 uniporter

Upon entering erythrocytes (red blood cells) through the GLUT-1 uniporter, glucose undergoes…

lucose enters erythrocytes via a uniporter. As the levels of glucose in the bloodstream decrease between meals, what happens to the glucose in the cells? O Glucose remains in the cell because the GLUT-1 uniporters are gated and the gates close at low glucose concentrations O Glucose leaves the cell through the GLUT-1 uniporter, traveling down the new concentration gradient. O Glucose remains in the cell because uniporters can only transport in one direction. O Glucose remains in the cell because it has been phosphorylated to Glucose-6- phosphate and no longer has affinity for the GLUT-1 uniporter

lucose enters erythrocytes via a uniporter. As the levels of glucose in the bloodstream decrease between meals, what happens to the glucose in the cells? O Glucose remains in the cell because the GLUT-1 uniporters are gated and the gates close at low glucose concentrations O Glucose leaves the cell through the GLUT-1 uniporter, traveling down the new concentration gradient. O Glucose remains in the cell because uniporters can only transport in one direction. O Glucose remains in the cell because it has been phosphorylated to Glucose-6- phosphate and no longer has affinity for the GLUT-1 uniporter

Curren'S Math For Meds: Dosages & Sol

11th Edition

ISBN:9781305143531

Author:CURREN

Publisher:CURREN

Chapter21: Heparin Infusion Calculations

Section: Chapter Questions

Problem 1SST

See similar textbooks

Similar questions

Explain why the proteins involved in blood clotting, fi brin and thrombin, are fi rst synthesized as the zymogens fi brinogen and prothrombin, respectively.
Rho activation is preceded by association of a Rho regulator to regions of the plasma membrane just “above” where the contractile ring will form. Which regulator (Rho GAP or Rho GEF) would you predict would be localized to this region of the cell? Briefly explain your reasoning.
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions What is the advantage of measuring autophosphorylation of the receptor rather than phosphorylation of the substrate?
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions How would you apply a TR-FRET assay to measure the in vitro kinase activity of VEGFR-2? Describe in steps the assay design and potential readout outcome.
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions How would you determine robustness of the assay and validate the assay?
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions While setting up your experiment, you accidentally discovered autophophorylation of receptor. What observation/results led you to believe that there was autophosphorylation of the receptor?
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions If you wanted to measure the kinase activity of VEGFR-2, what are some of the conventional methods/assays you would use?
In covid-19 myocarditis happened, and endothelial cell is in charge of inhibiting the inflammation, what will happen to the endocardium? It will be affected?
Here is a chloride cell in the gill epithelium of a fish. For reference, NKA = Na+/K+ ATPaseNKCC = Na+/K+/Cl- cotransporter. Given that the chloride cells of salt water fish have the NKCC transporter on the basal (bottom) side of the epithelium, what do you predict regarding the NKCC transporter in chloride cells of freshwater fish? A. The transporter must move chloride in the opposite direction, also from the bottom side of the cell. B. The NKCC transporter, as localized in salt water fish, could also work in freshwater fish. C. The transporter must move chloride in the opposite direction, but from the apical (top) side of the cell. D. A transporter is not needed to move Cl- ions into cells from fresh water.
It is not an easy matter to assign particular func-tions to specific components of the basal lamina, sincethe overall structure is a complicated composite materialwith both mechanical and signaling properties. Nidogen,for example, cross-links two central components of thebasal lamina by binding to the laminin γ-1 chain and totype IV collagen. Given such a key role, it was surprisingthat mice with a homozygous knockout of the gene fornidogen-1 were entirely healthy, with no abnormal phe-notype. Similarly, mice homozygous for a knockout of thegene for nidogen-2 also appeared completely normal. Bycontrast, mice that were homozygous for a defined muta-tion in the gene for laminin γ-1, which eliminated just thebinding site for nidogen, died at birth with severe defectsin lung and kidney formation. The mutant portion of thelaminin γ-1 chain is thought to have no other functionthan to bind nidogen, and does not affect laminin struc-ture or its ability to assemble into the basal lamina.…
Glucose transporter present in erythrocytes is- A. GLUT 1 B. GLUT 2 C. GLUT 3 D. GLUT 4
Describe the steps of TH2 activation in 2- 3 paragraph